AstraZeneca PLC (AZN)vsCG Oncology, Inc. Common stock (CGON)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
CGON
CG Oncology, Inc. Common stock
$66.74
+3.07%
HEALTHCARE · Cap: $5.70B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1453836% more annual revenue ($58.74B vs $4.04M). AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
CGON
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for CGON.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Revenue surging 409.2% year-over-year
Safe zone — low bankruptcy risk
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
0.0% margin — thin
ROE of -21.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : CGON
The strongest argument for CGON centers on Revenue Growth, Altman Z-Score. Revenue growth of 409.2% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : CGON
The primary concerns for CGON are EPS Growth, Profit Margin, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while CGON is a hypergrowth play — different risk/reward profiles.
CGON carries more volatility with a beta of 0.70 — expect wider price swings.
CGON is growing revenue faster at 409.2% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 32/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
CG Oncology, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
CG Oncology, Inc. is a clinical-stage biotechnology company dedicated to developing groundbreaking cancer therapies, with its lead product, CG0070, an innovative oncolytic virus therapy targeting non-muscle invasive bladder cancer. The company is poised to address significant unmet medical needs in oncology, underscoring its potential to improve patient outcomes and reshape treatment approaches. As CG Oncology advances through clinical trials and critical regulatory milestones, it leverages its proprietary technology platform to distinguish itself in the competitive oncology sector. This strategic emphasis on pioneering therapeutic options presents an attractive opportunity for institutional investors interested in advancements that could significantly impact cancer care.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?